A team led by Prof. Dr. Thomas Thum, Director of the Institute for Molecular and Translational Therapeutic Strategies at Hannover Medical School (MHH), has produced a synthetic antagonist called CDR132L, which can block the main switch for cardiac hypertrophy and reverse chronic heart failure.

Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it’s possible that giving them a little bit of extra support could keep them working correctly, and even reverse the damage they have caused.

Scientists have developed a way to turn the body’s own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions.

A pharmaceutical research team has identified a natural compound, timosaponin AIII (TAIII), that selectively eliminates CAR-T regulatory T cells.

An international team of researchers has identified an East African bat coronavirus capable of entering human cells.

Oregon Health & Science University researchers have developed a first-of-its-kind method to predict cancer patient survival using advanced molecular data from individual cells.

Researchers from Children’s Hospital of Philadelphia (CHOP) developed a new RNA sequencing strategy that can reveal how genetic variants disrupt gene function and improve the diagnosis of rare diseases.

A study by investigators at Mass General Brigham has found that a blood test of plasma phosphorylated tau 217 (pTau217), an Alzheimer’s disease biomarker, can predict the progression of amyloid PET scan changes and cognitive decline in cognitively healthy older adults.

Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that causes Down syndrome (DS)